Literature DB >> 10957661

External pneumatic compression and fibrinolysis in abdominal surgery.

M A Cahan1, D J Hanna, L A Wiley, D K Cox, L A Killewich.   

Abstract

INTRODUCTION: External pneumatic compression (EPC) devices prevent lower extremity deep venous thrombosis by increasing venous flow and thereby reducing stasis. Early studies suggested that they also enhance systemic fibrinolytic activity and thus prevent thrombus formation; more recent studies have been conflicting. The hypothesis of this study was that EPC devices enhance systemic fibrinolysis or reduce postoperative fibrinolytic impairment in patients undergoing abdominal surgical procedures.
METHODS: Each of 48 patients (98% male; mean age, 67 years) undergoing major intra-abdominal surgical procedures (36 bowel procedures, 12 aortic reconstructions) was prospectively randomized to one of three treatments for deep venous thrombosis prophylaxis: subcutaneous heparin injections (HEP group), use of a thigh-length sequential EPC device (EPC group), or both (HEP + EPC group). Antecubital venous samples were collected for measurement of systemic fibrinolytic activity on the day before surgery, after induction of anesthesia but before prophylaxis was initiated, and on postoperative days 1, 3, and 5. Fibrinolysis was assessed through measurement of the activities of the rate limiting fibrinolytic activator, tissue plasminogen activator, and its inhibitor plasminogen activator inhibitor-1 with amidolytic methods.
RESULTS: On the day before surgery, plasminogen activator inhibitor-1 activity was elevated in all groups in comparison with that in age-matched and sex-matched controls (20.3 +/- 0.6 AU/mL). In the HEP group, plasminogen activator inhibitor-1 activity was further elevated above the value for the day before surgery on postoperative day 1 (28.5 +/- 4.3 AU/mL; P =.04) and postoperative day 3 (25.1 +/- 1.9 AU/mL; P =.07). No significant decrease in plasminogen activator inhibitor-1 activity occurred in either group treated with EPC devices in comparison with the HEP group at any time. There were no changes in tissue plasminogen activator activity postoperatively in the HEP group and no significant increases in either EPC group at any point.
CONCLUSIONS: Reduced systemic fibrinolytic activity ("fibrinolytic shutdown") occurred in these patients after abdominal surgery; it was manifested as increased plasminogen activator inhibitor-1 activity. EPC devices did not enhance systemic fibrinolysis or prevent postoperative shutdown either by decreasing plasminogen activator inhibitor-1 activity or by increasing tissue plasminogen activator activity. These data suggest that EPC devices do not prevent deep venous thrombosis by fibrinolytic enhancement; effective prophylaxis is achieved only when the devices are used in a manner that reduces lower extremity venous stasis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10957661     DOI: 10.1067/mva.2000.107572

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  13 in total

Review 1.  Fibrinolysis Shutdown in Trauma: Historical Review and Clinical Implications.

Authors:  Hunter B Moore; Ernest E Moore; Matthew D Neal; Forest R Sheppard; Lucy Z Kornblith; Dominik F Draxler; Mark Walsh; Robert L Medcalf; Mitch J Cohen; Bryan A Cotton; Scott G Thomas; Christine M Leeper; Barbara A Gaines; Angela Sauaia
Journal:  Anesth Analg       Date:  2019-09       Impact factor: 5.108

Review 2.  Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation.

Authors:  Lara A Kahale; Maram B Hakoum; Ibrahim G Tsolakian; Charbel F Matar; Maddalena Barba; Victor E D Yosuico; Irene Terrenato; Francesca Sperati; Holger Schünemann; Elie A Akl
Journal:  Cochrane Database Syst Rev       Date:  2017-12-29

3.  A combination of heparin and an intermittent pneumatic compression device may be more effective to prevent deep-vein thrombosis in the lower extremities after laparoscopic cholecystectomy.

Authors:  Y Okuda; T Kitajima; H Egawa; S Hamaguchi; S Yamaguchi; H Yamazaki; K Ido
Journal:  Surg Endosc       Date:  2002-02-08       Impact factor: 4.584

Review 4.  Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism.

Authors:  Stavros Kakkos; George Kirkilesis; Joseph A Caprini; George Geroulakos; Andrew Nicolaides; Gerard Stansby; Daniel J Reddy
Journal:  Cochrane Database Syst Rev       Date:  2022-01-28

5.  Evidence-based compression: prevention of stasis and deep vein thrombosis.

Authors:  Rhys J Morris; John P Woodcock
Journal:  Ann Surg       Date:  2004-02       Impact factor: 12.969

Review 6.  Anticoagulation for people with cancer and central venous catheters.

Authors:  Lara A Kahale; Ibrahim G Tsolakian; Maram B Hakoum; Charbel F Matar; Maddalena Barba; Victor Ed Yosuico; Irene Terrenato; Francesca Sperati; Holger Schünemann; Elie A Akl
Journal:  Cochrane Database Syst Rev       Date:  2018-06-01

Review 7.  Anticoagulation for the initial treatment of venous thromboembolism in people with cancer.

Authors:  Maram B Hakoum; Lara A Kahale; Ibrahim G Tsolakian; Charbel F Matar; Victor Ed Yosuico; Irene Terrenato; Francesca Sperati; Maddalena Barba; Holger Schünemann; Elie A Akl
Journal:  Cochrane Database Syst Rev       Date:  2018-01-24

Review 8.  Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism.

Authors:  Stavros K Kakkos; Joseph A Caprini; George Geroulakos; Andrew N Nicolaides; Gerard Stansby; Daniel J Reddy; Ioannis Ntouvas
Journal:  Cochrane Database Syst Rev       Date:  2016-09-07

Review 9.  Parenteral anticoagulation in ambulatory patients with cancer.

Authors:  Elie A Akl; Lara A Kahale; Maram B Hakoum; Charbel F Matar; Francesca Sperati; Maddalena Barba; Victor E D Yosuico; Irene Terrenato; Anneliese Synnot; Holger Schünemann
Journal:  Cochrane Database Syst Rev       Date:  2017-09-11

Review 10.  Anticoagulation for perioperative thromboprophylaxis in people with cancer.

Authors:  Charbel F Matar; Lara A Kahale; Maram B Hakoum; Ibrahim G Tsolakian; Itziar Etxeandia-Ikobaltzeta; Victor Ed Yosuico; Irene Terrenato; Francesca Sperati; Maddalena Barba; Holger Schünemann; Elie A Akl
Journal:  Cochrane Database Syst Rev       Date:  2018-07-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.